Livial
(Tibolone)PreclinicalSmall molecule
PfizerTibolone is used to treat symptoms of menopause in women, such as hot flashes, night sweats, and mood changes. It also helps prevent bone loss that can occur after menopause.[1] Livial is currently being investigated across 3 indications[3], with its most advanced program in Preclinical.[1]
Livial is one of 109 small molecule programs targeting ART. It is currently in Preclinical.
3
Indications
21
Total Trials
1
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
96 competitors in ART
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Venclexta
AbbViePhase 3
Lorelco
SanofiPhase 3
Rituxan
RochePhase 3
Brukinsa
BBeOne Medicines
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Attruby
NNavire Pharma Inc., a BridgeBio company
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postmenopausal Women3 trials
Depression2 trials
Breast Cancer2 trials
ART2 trials
11 more indications
Trial1 trial
Bone Density1 trial
Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy
Completed·—·Phase 2·NCT00165204·50 enrolled
Overactive Bladder1 trial
Endometriosis1 trial
Lower Urinary Tract Symptom1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tibolone. EMBL-EBI & Wellcome Sanger Institute.
- [4]